Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole

被引:27
作者
Sanati, H
Messer, SA
Pfaller, M
Witt, M
Larsen, R
EspinelIngroff, A
Ghannoum, M
机构
[1] UNIV CALIF LOS ANGELES,HARBOR MED CTR,ST JOHNS CARDIOVASC RES CTR,DIV INFECT DIS,TORRANCE,CA 90509
[2] UNIV CALIF LOS ANGELES,HARBOR MED CTR,DEPT MED,DIV ALLERGY & IMMUNOL,TORRANCE,CA 90509
[3] UNIV IOWA,COLL MED,DEPT PATHOL,IOWA CITY,IA 52242
[4] UNIV SO CALIF,LOS ANGELES CTY MED CTR,SCH MED,DEPT MED,SECT COMMUNICABLE DIS,LOS ANGELES,CA 90033
[5] UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA
[6] UNIV CALIF SAN DIEGO,CALIF COLLABORAT TREATMENT GRP,LA JOLLA,CA 92093
[7] VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298
关键词
D O I
10.1128/JCM.34.5.1280-1282.1996
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We have developed a microdilution method for measuring the susceptibility of Cryptococcus neoformans to fluconazole. The present study evaluated the interlaboratory agreement of the results for the microdilution method obtained at three different sites and compared this method with the National Committee for Clinical Laboratory Standards M27-P reference method. Excellent interlaboratory agreement among the results obtained at the three sites was achieved with this method (83 and 96% agreement within 1 and 2 log(2) dilutions, respectively), An overall agreement of 90% between the microdilution method and the M27-P method was observed, demonstrating the comparability of the two methods, However, there are inherent problems with the M27-P method in relation to measuring C. neoformans susceptibility, including suboptimal growth of the organism in RPMI 1640, a longer incubation period, and a narrow range of MICs. On the basis of these data, the microdilution method tested in this study is recommended for inclusion in the National Committee for Laboratory Standards method for testing the antifungal susceptibility of C. neoformans.
引用
收藏
页码:1280 / 1282
页数:3
相关论文
共 17 条
[1]   INFECTIONS WITH CRYPTOCOCCUS-NEOFORMANS IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME [J].
CHUCK, SL ;
SANDE, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (12) :794-799
[2]   DECREASED FLUCONAZOLE SUSCEPTIBILITY OF A RELAPSE CRYPTOCOCCUS-NEOFORMANS ISOLATE AFTER FLUCONAZOLE TREATMENT [J].
CURRIE, BP ;
GHANNOUM, M ;
BESSEN, L ;
CASADEVALL, A .
INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1995, 4 (04) :318-319
[3]   TREATMENT OF CRYPTOCOCCAL MENINGITIS IN MICE WITH FLUCONAZOLE [J].
DEFERNANDEZ, EP ;
PATINO, MM ;
GRAYBILL, JR ;
TARBIT, MH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 18 (02) :261-270
[4]   CRYPTOCOCCAL INFECTIONS IN PATIENTS WITH ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME [J].
ENG, RHK ;
BISHBURG, E ;
SMITH, SM ;
KAPILA, R .
AMERICAN JOURNAL OF MEDICINE, 1986, 81 (01) :19-23
[5]   COLLABORATIVE COMPARISON OF BROTH MACRODILUTION AND MICRODILUTION ANTIFUNGAL SUSCEPTIBILITY TESTS [J].
ESPINELINGROFF, A ;
KISH, CW ;
KERKERING, TM ;
FROMTLING, RA ;
BARTIZAL, K ;
GALGIANI, JN ;
VILLAREAL, K ;
PFALLER, MA ;
GERARDEN, T ;
RINALDI, MG ;
FOTHERGILL, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (12) :3138-3145
[6]   SUSCEPTIBILITY TESTING OF CRYPTOCOCCUS-NEOFORMANS - A MICRODILUTION TECHNIQUE [J].
GHANNOUM, MA ;
IBRAHIM, AS ;
FU, Y ;
SHAFIQ, MC ;
EDWARDS, JE ;
CRIDDLE, RS .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (11) :2881-2886
[7]  
KWONCHUNG KJ, 1992, MED MYCOLOGY, P421
[8]   FLUCONAZOLE COMBINED WITH FLUCYTOSINE FOR TREATMENT OF CRYPTOCOCCAL MENINGITIS IN PATIENTS WITH AIDS [J].
LARSEN, RA ;
BOZZETTE, SA ;
JONES, BE ;
HAGHIGHAT, D ;
LEAL, MA ;
FORTHAL, D ;
BAUER, M ;
TILLES, JG ;
MCCUTCHAN, JA ;
LEEDOM, JM .
CLINICAL INFECTIOUS DISEASES, 1994, 19 (04) :741-745
[9]  
MILEFCHIK E, 1993, 9 INT C AIDS 4 STD W
[10]  
National Committee for Clinical Laboratory Standards, 1992, M27P NAT COMM CLIN L